Inva has activist Alex Denner in control of the board(5/5) and management which has been cut down to 2 people, includes CEO who is also Sarissa Executive. GSK has 30% ownership and probably will be likely buyer, they must have been waiting on Asthma indication approval which came earlier this month.
免責聲明
這些資訊和出版物並非旨在提供，也不構成TradingView提供或認可的任何形式的財務、投資、交易或其他類型的建議或推薦。請閱讀使用條款以了解更多資訊。
免責聲明
這些資訊和出版物並非旨在提供，也不構成TradingView提供或認可的任何形式的財務、投資、交易或其他類型的建議或推薦。請閱讀使用條款以了解更多資訊。